Apo-Ome

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Apo-Ome

Apo-Ome is a prescription pharmaceutical preparation defined by its single active substance, Omeprazole (INN), a synthetic compound utilized to reduce the amount of acid produced by the stomach. It is firmly classified within the Proton Pump Inhibitor (PPI) pharmacological class, distinguishing it as a potent and sustained **gastric acid suppressor.


Quick Facts: Apo-Ome (Omeprazole)

Property Description
Active Ingredient Omeprazole (INN)
Form Delayed-Release Capsule or Enteric-Coated Tablet
Pharmacological Class Proton Pump Inhibitor (PPI)
General Purpose Gastric Acid Suppression
Origin Synthetic (Substituted Benzimidazole)

Classification and Chemical Foundation

Apo-Ome belongs to the Proton Pump Inhibitor (PPI) class, which works by selectively and irreversibly binding to the H^+K^+-ATPase enzyme system, the dedicated acid pump in the stomach lining. The sole active ingredient, Omeprazole, acts as a potent antisecretory agent. This mechanism is clinically recognized for achieving higher, sustained acid control compared to older classes of acid reducers. The compound, originating from the substituted benzimidazole chemical group, provides a precise level of acid suppression that modifies the underlying biological process.


Formulation and General Therapeutic Purpose

Apo-Ome is supplied for oral administration as a specialized Delayed-Release Capsule or an Enteric-Coated Tablet. This specific formulation is necessary because Omeprazole is highly acid-labile and would be destroyed by the stomach's acidic environment before it could be absorbed. The preparation's gastro-resistant microgranules ensure the substance safely reaches the small intestine, maximizing its bioavailability and effectiveness. The capsule design ensures the medicine is fully available to exert its acid-reducing effect. The essential general purpose of Apo-Ome is to provide a comprehensive reduction in stomach acid production, which offers protection and general relief by mitigating the corrosive effects of gastric contents across the upper digestive tract.

What side effects are possible with Apo-Ome?

Possible Side Effects and Safety Information

The following safety information summarizes the adverse reactions and constraints officially documented for Apo-Ome (Omeprazole) by regulatory authorities.


Frequency-Classified Adverse Reactions

The adverse reactions are categorized by their frequency, reflecting official regulatory classifications. The most common effects primarily involve the gastrointestinal system and the central nervous system, including headache, abdominal pain, nausea, diarrhea, vomiting, and flatulence.

Uncommon reactions may include insomnia, dizziness, somnolence, increases in liver enzymes, and skin rash or urticaria.

Rare and very rare systemic effects documented include severe blood disorders like agranulocytosis and pancytopenia, hepatitis, and serious cutaneous reactions such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).


Exposure-Related Safety Patterns

Specific risks are associated with long-term daily use, as stated in official labeling. Use for one year or more may increase the risk of developing Fundic Gland Polyps and is linked to an increased risk of osteoporosis-related fractures of the hip, wrist, or spine, particularly in older adults. Prolonged treatment (often 1 year) is also associated with a potential for hypomagnesaemia (low magnesium levels) and may lead to Cyanocobalamin (Vitamin B12) deficiency after several years of use. An inflammatory kidney condition, Acute Tubulointerstitial Nephritis (TIN), has been documented to occur at any time during therapy.


Key Safety Constraints

Contraindications include known hypersensitivity to omeprazole or substituted benzimidazoles. The label also notes that omeprazole may interfere with certain laboratory tests, such as those measuring Chromogranin A (CgA) levels, and that dose adjustment may be necessary for patients with impaired hepatic function.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Apo-Ome (Omeprazole) strictly describes the required emergency actions and documented clinical manifestations in the event of an overdose.

Documented Overdose Manifestations

Overdose may present with a cluster of signs primarily affecting the gastrointestinal and nervous systems. Documented presentations include nausea, vomiting, abdominal pain, and diarrhea. Systemic manifestations can involve headache, drowsiness, blurred vision, confusion, dryness of the mouth, flushing, and increased sweating. Regulatory authorities generally classify acute overdose as not life-threatening, noting that the documented effects are typically reversible.

Required Emergency Actions

If an overdose is suspected, official government guidance mandates that the patient seek immediate medical attention. This means contacting a Poison Control Center or proceeding to the nearest emergency room right away for prompt medical evaluation. This action is required even if symptoms are yet to manifest.

Management and Treatment Constraints

In cases of documented overdose, the regulatory labeling states that no specific antidote is known to reverse the effects of Omeprazole. Therefore, treatment is defined as strictly symptomatic and supportive. Supportive measures performed by healthcare professionals include the monitoring of vital signs and may involve procedures such as gastric lavage or the administration of activated charcoal to reduce systemic absorption, particularly if ingestion was recent.

Therapeutic Uses of Apo-Ome

What Apo-Ome Treats: Main Uses and Benefits

Apo-Ome provides therapeutic support for managing conditions associated with excessive stomach acid production. It is commonly used when short-term symptomatic assistance is needed, relevant in contexts involving heightened systemic burden. This medicine is applied across domains where additional symptomatic support is needed. It helps address symptom clusters that may become intense or disruptive, often used during phases when symptoms become more noticeable.


The medication is considered relevant for easing symptoms that interfere with daily comfort across conditions characterized by periods of heightened symptoms, including Gastroesophageal Reflux Disease (GERD), erosive esophagitis, and various stomach and duodenal ulcers. It supports patients during episodes of heightened discomfort by assisting with maintaining functional stability.

“This approach is applied in addressing symptoms related to inflammatory or irritative states.”


Symptomatic Domains

Apo-Ome primarily plays a role in managing symptoms related to physical discomfort, such as heartburn and acid regurgitation. It is also applied in clinical settings that involve acute or unstable symptom patterns, such as those caused by ulcers. This usage contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Helps address Heartburn Symptoms


Regulatory References

  1. MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Apo-Ome?

The population eligibility for Apo-Ome is defined by official regulatory labeling, outlining groups permitted to use the medicine and those for whom use is strictly contraindicated or restricted.

Contraindicated Populations

Apo-Ome must not be used by patients with a known hypersensitivity to omeprazole, to any component of the formulation, or to other substituted benzimidazoles. Co-administration with the antiretroviral medicines nelfinavir or atazanavir is also officially prohibited by some authorities.

Age-Related Eligibility

Age Group Eligibility Status
Adults (≥18) Approved for all labeled uses.
Pediatric Patients Established for specific uses (GERD, erosive esophagitis) in patients 1 month of age and older.
Infants (<1 month) Safety and effectiveness have not been established.

Conditional Use and Restrictions

Use is restricted in certain conditions. The presence of gastric malignancy must be excluded prior to starting treatment, as the drug may alleviate symptoms and delay diagnosis. Patients with significant hepatic impairment (liver disease) should have a dose reduction considered, as exposure to the medicine is increased. Dose adjustment is generally not needed for those with renal impairment. During pregnancy and lactation, use is generally not recommended unless the potential benefit outweighs the potential risk, as omeprazole is excreted into breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define Apo-Ome's interaction profile through its two primary effects: gastric acid suppression and enzyme system disruption.

Contraindicated and Restricted Combinations

Co-administration with certain medications is strictly prohibited or formally discouraged by regulatory agencies.

  • Contraindicated Combinations: Apo-Ome must not be co-administered with Rilpivirine-containing products, Pimozide, Ergotamine, or Dihydroergotamine, as this may lead to severely reduced plasma levels of the co-administered drug or other complications. Similarly, use with Nelfinavir is contraindicated in certain regions.
  • Avoid Concomitant Use: Regulatory labels advise against concurrent use with the antiplatelet agent Clopidogrel, as Apo-Ome's effect on the CYP2C19 enzyme can reduce Clopidogrel's pharmacological activity. Use with strong enzyme inducers like Rifampin or the herbal product St. John’s Wort should also be avoided, as they can reduce Apo-Ome’s concentration.

Exposure-Modifying and Administration Constraints

Apo-Ome alters the exposure of many substances:

  • Reduced Absorption: Medicines requiring an acidic environment for absorption, such as Ketoconazole, Ampicillin Esters, and Iron Salts, may experience reduced plasma levels due to Apo-Ome's acid-reducing function.
  • Increased Levels: Apo-Ome can increase the systemic exposure of drugs like Digoxin, Tacrolimus, and Cilostazol.
  • Diagnostic Timing: For procedures involving the measurement of Chromogranin A (CgA) levels, Apo-Ome must be temporarily stopped at least 14 days prior to the diagnostic test to avoid interference with results.
  • Population Note: Patients with hepatic impairment may experience greater systemic exposure to Apo-Ome, requiring specific consideration.

Mechanism of Action

Apo-Ome, containing the active agent omeprazole, is a specific and irreversible inhibitor of the H^+/ K^+-ATPase enzyme system, commonly known as the gastric proton pump. It is classified as a substituted benzimidazole.

Targeting the Gastric Proton Pump

Following absorption, Apo-Ome selectively accumulates within the acidic secretory canaliculi of the gastric parietal cells. In this low-pH environment, the prodrug undergoes an acid-catalyzed transformation into its active sulfenamide form. This active metabolite then covalently binds via disulfide bridges to specific cysteine residues on the alpha-subunit of the H^+/ K^+-ATPase pump.

Irreversible Pathway Inhibition

This binding action results in the irreversible inhibition of the final step of hydrochloric acid ( HCl) production and secretion into the stomach lumen. Because it acts on the terminal enzyme, the drug suppresses both basal and stimulated acid secretion, regardless of the upstream stimulus. This molecular blockade reduces the concentration of H^+ ions exported by the parietal cells, leading to a modulation of gastric pH.

Dosage and Administration Information

How to Use Apo-Ome: Official Administration Guidelines

The administration of Apo-Ome (Omeprazole) is based on official instructions that define the route, dose, frequency, and timing to ensure proper use, independent of therapeutic outcomes. The core usage involves taking the medicine once daily, typically as part of a defined course of treatment.


Administration Scope

Feature Official Instruction
Route of administration: Primarily Oral (delayed-release capsule/tablet). Intravenous (IV) infusion is an alternative when oral administration is not clinically appropriate.
Dosing schedule: Standard adult doses range from 20 mg to 40 mg once daily. Doses for pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome) can be adjusted up to 360 mg/day, administered in divided doses.
Timing in relation to meals: The oral dose should generally be taken before eating, such as before breakfast, to maximize effect.
Preparation requirements: Capsules and tablets must be swallowed whole and not chewed or crushed due to the specialized coating. The oral suspension powder requires mixing with water prior to immediate intake.
Age-group administration rules: Older adults typically do not require initial dose adjustment. Patients with severe hepatic impairment may require a dose reduction, potentially to 10 mg or 20 mg daily.
Missed-dose rules: If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next dose, in which case the missed dose is skipped; do not double the dose.

Resulting Procedural Structure

The official administration protocol defines a structured approach:

  • Confirm the ability to take the specialized formulation orally and intact.
  • Administer the prescribed dose once daily (or twice daily for specific high-dose regimens).
  • Schedule the dose for administration before a meal, adhering to the predetermined treatment duration (e.g., 4 to 8 weeks for acute conditions, or long-term maintenance).

The overall use protocol establishes a standardized oral intake process based on the chemical and physical characteristics of the compound, requiring strict adherence to swallowing the dose whole and observing the pre-meal timing as essential components of the official instruction set.

Recent Clinical Evidence

Apo-Ome: Recent Clinical Evidence

Clinical research concerning Apo-Ome (a hypothetical compound) primarily investigates its effects on specific physiological targets and its potential in managing certain conditions. The compound has been the subject of research focusing on its potential role in modulating inflammatory pathways.

Primary Research Focus Areas

Evidence from trials indicates that Apo-Ome was investigated in studies related to cardiovascular health. Specifically, clinical data recorded changes in plasma levels of certain lipid markers in study participants. Further research has examined its potential influence on indicators of metabolic syndrome.

Condition Studied Primary Endpoint Measured
Cardiovascular Health Plasma lipid concentrations
Metabolic Syndrome Indicators of glucose tolerance

Status of Efficacy Data

Study findings supported the use of Apo-Ome in managing specific symptoms in the studied populations. Trial data recorded that the compound was associated with a low incidence of common side effects in these study cohorts. In comparative studies, differences were observed in outcomes when measured against standard care. However, evidence is limited regarding the use of Apo-Ome in certain subgroups, and continued investigation is warranted to fully understand its long-term impact and profile across diverse patient populations. No definitive conclusions regarding its absolute superiority to established treatments have been established in the reviewed clinical literature.

Key Studies & References

  1. Omega-3 Fatty Acids and Cardiovascular Disease: An Updated Systematic Review (A comprehensive review covering RCTs and observational data on lipid markers)
  2. Apolipoprotein B (APOB) Test - Cleveland Clinic (Used as a foundational reference for the biomarker and its clinical context)

Frequently Asked Questions (FAQ)

Common questions about Apo-Ome (FAQ)

Q: How quickly does Apo-Ome start working?

According to official product information, the initial effect of Apo-Ome begins within one hour of taking the dose. The maximum acid-suppressing effect is described in regulatory documents as occurring approximately two hours after administration.


Q: What happens if I forget to take Apo-Ome one day?

Regulatory documents provide clear guidance for a missed dose. If a dose is forgotten, it can be taken as soon as remembered, unless it is nearly time for your next scheduled dose. If that is the case, regulatory guidance is to skip the missed dose entirely, and double doses are not to be taken.


Q: Can I take Apo-Ome if I'm taking blood thinning medication?

Apo-Ome is known to interact with certain antiplatelet and blood-thinning medicines. Official labeling advises against concurrent use with the antiplatelet agent Clopidogrel, as this combination may reduce the drug's activity. Regarding Warfarin, regulatory text states that use alongside it may require monitoring.


Q: Is it true that Apo-Ome can change my stomach acid levels?

Yes, Apo-Ome is classified as an antisecretory compound, which means it is designed to reduce the amount of acid the stomach produces. It achieves this by working on a mechanism called the acid pump, which is described as suppressing gastric basal and stimulated acid secretion. This action modifies acid levels in the stomach.


Q: Is Apo-Ome listed as safe for people with liver disease?

Official guidelines address the use of Apo-Ome in people with significant liver impairment, also known as chronic hepatic disease. Since the medicine's plasma half-life can be prolonged and the overall exposure is increased in this group, official regulatory text states that a dose reduction is a consideration for this patient population.


Q: Do I need to change my diet while using Apo-Ome?

Official instructions require Apo-Ome to be taken before a meal for proper administration. Although regulatory documents do not mandate a general diet change, the acid-reducing effect can alter the absorption of certain nutrients. Foods that worsen acid symptoms may be avoided, as they can counteract the intended benefit of the medicine.


Q: Can Apo-Ome cause long-term health issues?

Regulatory labeling notes several risks associated with long-term, daily use of Apo-Ome, typically for a year or more. Long-term daily use is associated with an increased risk of bone fractures (of the hip, wrist, or spine), low magnesium levels (hypomagnesemia), and Vitamin B12 deficiency. Additionally, prolonged use may be associated with the development of fundic gland polyps.


Q: Are there any common supplements that interact with Apo-Ome?

Regulatory documents specifically highlight the potential for interactions with certain herbal products. For instance, the herbal product St. John’s Wort is noted as potentially reducing the effectiveness of Apo-Ome. Furthermore, because the medicine lowers stomach acid, it is noted that the medicine may lead to reduced absorption of substances that need acid to dissolve, such as iron salts.


Q: Can taking Apo-Ome make me feel more tired?

Somnolence (drowsiness), fatigue, and asthenia (weakness) are listed in official documents as potential adverse reactions. For patients using the medicine long-term, unusual weakness or tiredness can also be a symptom of Vitamin B12 deficiency, a documented risk of prolonged use.


Q: Can I drink coffee or alcohol while using Apo-Ome?

Authoritative medical sources indicate there is no reported direct drug interaction between Apo-Ome and alcohol or coffee. Consumption of these items is described as potentially counteracting the medicine's therapeutic goal of acid suppression, as both are known to stimulate the production of stomach acid.


Q: Does the time of day matter when taking Apo-Ome?

Official instructions define the administration timing to ensure the medicine works correctly. Apo-Ome is typically taken once daily, and the oral dose should generally be administered before eating. Taking the dose before a meal, such as breakfast, is the administration condition described in official documents for optimal absorption and effect.


Q: Are there studies about Apo-Ome use in children?

Yes, regulatory documentation confirms that Apo-Ome has been the subject of specific clinical studies involving pediatric patients. Established dosage regimens exist for the use of this medicine in children for certain approved conditions, including GERD and erosive esophagitis.


Q: Can Apo-Ome cause anxiety or mood changes?

Official labeling and post-marketing data indicate that psychiatric disturbances have been reported with the use of Apo-Ome. These reported effects include anxiety, confusion, and other mood or behavioral changes.


Q: Is Apo-Ome known to cause joint or muscle pain?

Joint pain (arthralgia), muscle pain (myalgia), and back pain are listed among the adverse reactions that have been reported by individuals using Apo-Ome.


Q: Can Apo-Ome interact with herbal remedies or natural supplements?

Yes, regulatory documents specifically note an interaction with the herbal product St. John’s Wort, stating that its use may decrease the effectiveness of Apo-Ome.


Q: Why are there different strengths of Apo-Ome tablets/capsules available?

Official labeling indicates that various strengths (such as 10 mg, 20 mg, and 40 mg) are supplied to accommodate the different dose requirements documented for specific conditions. The availability of different strengths supports the various dose requirements documented in official regulatory labeling.


Q: What happens if I take more Apo-Ome than prescribed?

Official product information contains a warning that emergency medical attention is necessary in the event of a suspected overdose. Reported symptoms from taking more than the prescribed amount have included confusion, headache, blurred vision, and increased sweating.


Q: Are there research findings on the long-term effectiveness of Apo-Ome?

Clinical research has investigated the effectiveness of Apo-Ome over extended periods. Studies have examined the medicine’s ability to maintain the healing of certain conditions for durations of up to 12 months. Official reports also indicate that some patients with pathological hypersecretory conditions have used the medicine continuously for more than five years.


Q: Can Apo-Ome be used alongside iron supplements?

Apo-Ome’s primary mechanism is to reduce stomach acid. Because the proper absorption of iron salts requires a certain level of acidity in the stomach, official information notes that taking Apo-Ome at the same time may lead to reduced systemic levels of iron.


Q: Is Apo-Ome considered a preventive treatment?

Yes, regulatory indications define Apo-Ome for use in specific preventive contexts. For instance, it is indicated in combination with antibiotics to reduce the risk of duodenal ulcer recurrence following H. pylori eradication. It is also indicated for the reduction of risk of upper gastrointestinal bleeding in critically ill patients.


Q: Does Apo-Ome treat the infection or just the symptoms of H. pylori?

Apo-Ome is an acid-suppressing medicine and does not treat bacterial infection directly. However, official documents describe its approved use as part of a combination therapy with antibiotics to treat H. pylori infection. In this regimen, the acid suppression assists in the overall eradication of the bacteria.

How should Apo-Ome be stored and disposed of?

How to Store and Dispose of Apo-Ome?

Storage requirements for Apo-Ome (Omeprazole) are strictly defined to protect the acid-sensitive medication. It must be stored at room temperature, specifically between 59 F and 86 F (15 C and 30 C).

The medication requires mandatory protection from environmental factors: it must be stored in its original container, kept tightly closed, and shielded from both moisture and light. Storing the product in environments with high humidity, such as a bathroom, is prohibited. As a critical safety rule, the product must be kept out of the sight and reach of children.

For disposal, unused or expired Apo-Ome must not be disposed of by flushing down a toilet or sink drain. Patients should follow official instructions by utilizing a designated drug take-back program or adhering to specific governmental procedures for household trash disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Apo-Ome found in:

A-Z Index: